CRDF
Cardiff Oncology, Inc.
There isn't enough reported data to score CRDF yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CRDF Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CRDF's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CRDF PE Valuation
CRDF has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CRDF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect CRDF's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CRDF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.55 | +$0.25 |
| Q2 2026 | -$0.60 | +$0.28 |
| Q1 2026 | -$0.67 | +$0.26 |
| Q4 2025 | -$0.69 | +$0.26 |
| Q3 2025 | -$0.80 | +$0.14 |
| Q2 2025 | -$0.88 | +$0.03 |
| Q1 2025 | -$0.93 | -$0.03 |
| Q4 2024 | -$0.95 | -$0.02 |
CRDF is still losing money, but far less than before: $0.55 per share over the past year, against $2.80 at its worst in late 2019.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CRDF on earnings quality, reporting a profit while its opponent remains loss making.
CRDF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $171K | +43% |
| Q2 2026 | $104K | -14% |
| Q1 2026 | $41K | -62% |
| Q4 2025 | $243K | +61% |
| Q3 2025 | $120K | -27% |
| Q2 2025 | $121K | -26% |
| Q1 2025 | $109K | -47% |
| Q4 2024 | $151K | -3.2% |
CRDF's revenue is growing: $171,000 last quarter, up 43% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -5391% | +4587 points |
| Q2 2026 | -9245% | +2967 points |
| Q1 2026 | -31341% | -18147 points |
| Q4 2025 | -3221% | +5105 points |
| Q3 2025 | -9978% | -2341 points |
| Q2 2025 | -12212% | -4516 points |
| Q1 2025 | -13195% | -7861 points |
| Q4 2024 | -8326% | -1703 points |
CRDF's operating margin was −5391% last quarter, up 4587 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CRDF on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CRDF on profitability, with a higher operating margin.
CRDF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.9M | +$974K |
| Q4 2025 | -$6M | +$4.3M |
| Q3 2025 | -$10.9M | -$396K |
| Q4 2024 | -$10.3M | -$3.1M |
| Q3 2024 | -$10.5M | -$2.2M |
| Q2 2024 | -$9.2M | -$1.8M |
| Q1 2024 | -$7.8M | +$847K |
| Q4 2023 | -$7.1M | +$2.3M |
NVO has the stronger cash trend. Its trailing FCF is down 14% versus its history, compared with CRDF at down 29%.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
CRDF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +11% | +7.8M shares |
| 1 year | +14% | +9.3M shares |
| 3 years | +71% | +31.5M shares |
| 5 years | +97% | +37.4M shares |
| Available history | +669% | +66.3M shares |
CRDF has 76M diluted shares, up 14% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CRDF on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CRDF Net Leverage
CRDF's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CRDF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 8.2 | Oversold |
CRDF's weekly RSI is 34 (neutral) and its Stochastic is 8 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CRDF PE vs Healthcare Sector
CRDF has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CRDF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.96 | 24% below |
| 20 week MA | $1.01 | 28% below |
| 50 week MA | $1.57 | 54% below |
| 100 week MA | $2.35 | 69% below |
| 200 week MA | $2.29 | 68% below |
CRDF is in a downtrend: it's below all five of its weekly moving averages, and 68% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over CRDF on trend strength, trading above more of its moving averages.
CRDF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.28 | $18.9 | +1377% |
| 2021 | $18.9 | $6.45 | -66% |
| 2022 | $6.45 | $1.26 | -80% |
| 2023 | $1.26 | $1.48 | +17% |
| 2024 | $1.48 | $4.32 | +192% |
| 2025 | $4.32 | $3.17 | -27% |
| 2026 YTD | $3.17 | $0.73 | -77% |
CRDF's yearly returns have swung widely, from +1377% in 2020 to −80% in 2022. It's down 77% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over CRDF on returns for 2026, with the stronger performance.